Vitamin D for the management of multiple sclerosis

Selected health behaviors moderate the progression of functional limitations in persons with multiple sclerosis: Eleven years of annual follow-up

“…In addition, exercise (higher) and health responsibility (lower) scores were associated with slower rates of functional limitation progression. Consistent with recent Cochrane reviews [7,8], self-reported nutrition behaviors had no effect on functional limitations at Year 11 or the rate of progression.…”

Selected health behaviors moderate the progression of functional limitations in persons with multiple sclerosis: Eleven years of annual follow-up

“…In addition, exercise (higher) and health responsibility (lower) scores were associated with slower rates of functional limitation progression. Consistent with recent Cochrane reviews [7,8], self-reported nutrition behaviors had no effect on functional limitations at Year 11 or the rate of progression.…”

Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol

“…Lower VitD levels are also present in other autoimmune pathologies [ 10 ]. These findings are consistent with the remarkable systemic immunomodulatory potential [ 11 ] and neuroprotective ability of VitD [ 12 , 13 ], suggesting possible benefits for MS patients [ 14 , 15 , 16 ]. However, despite the considerable interest in using VitD as an add-on therapy for MS, and the numerous clinical assays previously performed, the benefits of its supplementation in patients are still a matter of debate and deserve further investigation [ 17 , 18 ].…”

Vitamin D supplementation in multiple sclerosis: an expert opinion based on the review of current evidence

“…A meta-analysis by McLaughlin et al [61] showed no statistically significant difference in new gadolinium enhancing T1 lesions between vitamin D treated MS patients and control groups. Similar to the results on relapses and EDSS progression, The Cochrane review by Jagannath et al [65] reported no benefit of vitamin D supplements on the number of MRI gadolinium enhancing T1 lesions, although again the certainty of the evidence was deemed very low.…”

Selected health behaviors moderate the progression of functional limitations in persons with multiple sclerosis: Eleven years of annual follow-up

“…In addition, exercise (higher) and health responsibility (lower) scores were associated with slower rates of functional limitation progression. Consistent with recent Cochrane reviews [7,8], self-reported nutrition behaviors had no effect on functional limitations at Year 11 or the rate of progression.…”

Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol

“…Lower VitD levels are also present in other autoimmune pathologies [ 10 ]. These findings are consistent with the remarkable systemic immunomodulatory potential [ 11 ] and neuroprotective ability of VitD [ 12 , 13 ], suggesting possible benefits for MS patients [ 14 , 15 , 16 ]. However, despite the considerable interest in using VitD as an add-on therapy for MS, and the numerous clinical assays previously performed, the benefits of its supplementation in patients are still a matter of debate and deserve further investigation [ 17 , 18 ].…”

Vitamin D supplementation in multiple sclerosis: an expert opinion based on the review of current evidence

“…A meta-analysis by McLaughlin et al [61] showed no statistically significant difference in new gadolinium enhancing T1 lesions between vitamin D treated MS patients and control groups. Similar to the results on relapses and EDSS progression, The Cochrane review by Jagannath et al [65] reported no benefit of vitamin D supplements on the number of MRI gadolinium enhancing T1 lesions, although again the certainty of the evidence was deemed very low.…”

Selected health behaviors moderate the progression of functional limitations in persons with multiple sclerosis: Eleven years of annual follow-up

“…In addition, exercise (higher) and health responsibility (lower) scores were associated with slower rates of functional limitation progression. Consistent with recent Cochrane reviews [7,8], self-reported nutrition behaviors had no effect on functional limitations at Year 11 or the rate of progression.…”

Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol

“…Lower VitD levels are also present in other autoimmune pathologies [ 10 ]. These findings are consistent with the remarkable systemic immunomodulatory potential [ 11 ] and neuroprotective ability of VitD [ 12 , 13 ], suggesting possible benefits for MS patients [ 14 , 15 , 16 ]. However, despite the considerable interest in using VitD as an add-on therapy for MS, and the numerous clinical assays previously performed, the benefits of its supplementation in patients are still a matter of debate and deserve further investigation [ 17 , 18 ].…”

Vitamin D supplementation in multiple sclerosis: an expert opinion based on the review of current evidence

“…A meta-analysis by McLaughlin et al [61] showed no statistically significant difference in new gadolinium enhancing T1 lesions between vitamin D treated MS patients and control groups. Similar to the results on relapses and EDSS progression, The Cochrane review by Jagannath et al [65] reported no benefit of vitamin D supplements on the number of MRI gadolinium enhancing T1 lesions, although again the certainty of the evidence was deemed very low.…”